Cargando…
P918: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL
Autores principales: | Cerchione, Claudio, Nappi, Davide, Marchesini, Matteo, Ronconi, Sonia, Cangini, Delia, Ceccolini, Michela, Feliciani, Giacomo, Prochowski Iamurri, Andrea, Matuozzo, Claudia, Mammoli, Fabiana, Frabetti, Federica, Paganelli, Giovanni, Matteucci, Federica, Pallotti, Caterina, Scarpi, Emanuela, Pazzi, Chiara, Barone, Domenico, Romeo, Antonino, Simonetti, Giorgia, Musuraca, Gerardo, Martinelli, Giovanni, Rossi, Alice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431137/ http://dx.doi.org/10.1097/01.HS9.0000970576.19651.f8 |
Ejemplares similares
-
P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL
por: Cerchione, Claudio, et al.
Publicado: (2023) -
PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS’ ERA
por: Cerchione, C., et al.
Publicado: (2022) -
PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
por: Cerchione, C., et al.
Publicado: (2022) -
PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022) -
PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET
por: Cerchione, C., et al.
Publicado: (2022)